A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

To join this study, you would generally need to be an adult with follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has either returned or not responded to past treatments. Specifically, your lymphoma diagnosis needs to be recent, and you should have already received at least one prior treatment that included certain medications like anti-CD20 and an alkylating agent. If you have follicular lymphoma, you might qualify after one previous treatment if your disease has certain high-risk features, or after two or more treatments if one included the specific medications mentioned. If you have marginal zone lymphoma, you'd typically need two or more prior treatments with those specific medications, or if your lymphoma came back after a stem cell transplant. You also need to be generally fit and healthy enough, meaning your body's main organs are working well, and you have good overall daily function.

There are also some reasons why you might not be able to join. For example, if your lymphoma has spread to certain parts of your central nervous system, or if you have another type of lymphoma called Diffuse Large B-cell Lymphoma (DLBCL) combined with follicular lymphoma. You also wouldn't be able to participate if you've had a type of cell therapy like CAR T-cell therapy before, or if you have certain active infections like HIV, Hepatitis B or C, or uncontrolled other infections. Other reasons include specific heart conditions, active autoimmune diseases needing strong medication, or if you have certain other serious health issues that could make the treatment unsafe for you.

If you decide to take part in this study, your journey will be split into three main parts. First, there's the 'Pretreatment' period. This involves several checks and tests to confirm you're suitable for the study. A key part of this is a procedure called 'leukapheresis,' where some of your white blood cells are collected. These cells are then sent away to be specially prepared for the JCAR017 treatment.

Next is the 'Treatment' period. Before you receive JCAR017, you'll have a short course of chemotherapy medications (Fludarabine and Cyclophosphamide). This is done to prepare your body for the cell therapy. A few days later, you'll receive the JCAR017 cells as a one-time infusion (like a drip). You'll then be closely monitored for about a month to check how you're responding and for any immediate side effects.

Finally, there's a long 'Posttreatment' period, which lasts for five years. During this time, you'll have regular check-ups with the study team. These visits will involve various tests and assessments to see how your lymphoma is doing, whether the treatment continues to work, and to monitor your long-term health and any late side effects. You'll be supported throughout the entire study.